1. A purified and isolated polynucleotide encoding cGB-PDE.
2. The polynucleotide of claim 1 which is a DNA sequence.
3. The DNA sequence of claim 2 which is a cDNA sequence or a biological replica thereof.
4. The DNA sequence of claim 2 which is a genomic DNA sequence or a biological replica thereof.
5. An RNA transcript of the genomic DNA sequence of claim 4.
6. The DNA sequence of claim 2 which is a wholly or partially chemically synthesized DNA sequence or a biological replica thereof.
7. The DNA sequence of claim 4 further comprising an endogenous expression control DNA sequence.
8. A DNA vector comprising a DNA sequence according to claim 2.
9. The vector of claim 8 wherein said DNA sequence is operatively linked to an expression control DNA sequence.
10. A host cell stably transformed or transfected with a DNA sequence according to claim 7 in a manner allowing the expression in said host cell of cGB-PDE polypeptide possessing a ligandreceptor binding biological activity or immunological property specific to cGB-PDE.
11. A method for producing cGB-PDE polypeptide, said method comprising growing a host cell according to claim 10 in a suitable nutrient medium and isolating cGB-PDE polypeptide from said cell or the medium of its growth.
12. A polypeptide or peptide capable of specifically binding to cGB-PDE.
13. An antibody substance according to claim 12.
14. A monoclonal antibody according to claim 13.
15. A hybridoma cell line producing a monoclonal antibody according to claim 14.
16. A humanized antibody substance according to claim 13.
17. An antisense polynucleotide specific for a polynucleotide encoding cGB-PDE.
18. A DNA sequence encoding cGB-PDE and selected from the group consisting of:
(a) the DNA sequence set out in SEQ ID NO: 9 or 22;
(b) a DNA which hybridizes under stringent conditions to the DNA of (a); and
(c) a DNA sequence which, but for the redundancy of the genetic code, would hybridize under stringent conditions to a DNA sequence of (a) or (b).
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A tobacco solution for use in a vaporization delivery mechanism, the tobacco solution comprising:
a. water present at about 0.01% to about 20% of the tobacco solution;
b. an effective serving of tobacco constituents, wherein the effective serving is at least 0.5% of the tobacco solution; and
c. a remainder of the tobacco solution comprising at least 70 percent of a polysorbate composition.
2. The tobacco solution of claim 1, wherein the tobacco constituents are selected from the group consisting of nicotine and a monoamine oxidase inhibitor.
3. The tobacco solution of claim 1, wherein the effective serving of the tobacco constituents is between about 0.5% to about 20% of the tobacco solution.
4. The tobacco solution of claim 1, wherein the effective serving of the tobacco constituents is between about 0.5% to about 15% of the tobacco solution.
5. The tobacco solution of claim 1, wherein the effective serving of the tobacco constituents is between about 5% to about 10% of the tobacco solution.
6. The tobacco solution of claim 1, wherein the tobacco solution comprises about 2% to about 18% water.
7. The tobacco solution of claim 1, wherein the tobacco solution comprises about 5% to about 15% water.
8. A tobacco solution for use in a vaporization delivery mechanism, the tobacco solution comprising:
a. water present at about 0.01% to about 20% of the tobacco solution;
b. an effective serving of tobacco constituents, wherein the effective serving is a least 0.5% of the tobacco solution; and
c. a remainder of the tobacco solution comprising a polysorbate composition,
wherein the polysorbate composition comprises at least 70% polysorbate 20.
9. The tobacco solution of claim 8, wherein the tobacco constituents are selected from the group consisting of nicotine and a monoamine oxidase inhibitor.
10. The tobacco solution of claim 8, wherein the effective serving of the tobacco constituents is between about 0.5% to about 20% of the tobacco solution.
11. The tobacco solution of claim 8, wherein the effective serving of the tobacco constituents is between about 0.5% to about 15% of the tobacco solution.
12. The tobacco solution of claim 8, wherein the effective serving of the tobacco constituents is between about 5% to about 10% of the tobacco solution.
13. The tobacco solution of claim 8, wherein the tobacco solution comprises about 2% to about 18% water.
14. The tobacco solution of claim 8, wherein the tobacco solution comprises about 5% to about 15% water.
15. A tobacco solution for use in a vaporization delivery mechanism, the tobacco solution comprising:
a. water present at about 0.01% to about 20% of the tobacco solution;
b. an effective serving of tobacco constituents, wherein the effective serving is at least 0.5% of the tobacco solution; and
c. a remainder of the tobacco solution comprising a polysorbate composition,
wherein the polysorbate composition comprises at least 70% polysorbate 80.
16. The tobacco solution of claim 15, wherein the tobacco constituents are selected from the group consisting of nicotine and a monoamine oxidase inhibitor.
17. The tobacco solution of claim 15, wherein the effective serving of the tobacco constituents is between about 0.5% to about 20% of the tobacco solution.
18. The tobacco solution of claim 15, wherein the effective serving of the tobacco constituents is between about 0.5% to about 15% of the tobacco solution.
19. The tobacco solution of claim 15, wherein the effective serving of the tobacco constituents is between about 5% to about 10% of the tobacco solution.
20. The tobacco solution of claim 15, wherein the tobacco solution comprises about 2% to about 18% water.
21. The tobacco solution of claim 15, wherein the tobacco solution comprises about 5% to about 15% water.